# Centre for Pharmacoepidemiology, Karolinska Institutet (CPE-KI)

**First published:** 24/03/2010

**Last updated:** 23/04/2024

Institution Educational Institution Laboratory/Research/Testing facility

Not-for-profit

### Institution identification

Institution ID	
47342	
Institution countries	
Sweden	
Type of institution	
Educational Institution	
Laboratory/Research/Testing facility	
Not-for-profit	
Institution role	
Researcher	

#### **Institution website**

#### **ENCePP** partner

Yes

### Institution description

CPE is lead by acting director Caroline Öberg. CPE's steering group includes representatives from academia, government agencies, regulatory authorities, pharmaceutical industry and Stockholm's county council. CPE strives to meet the demands from both national and international stakeholders in society and industry concerning data on drug safety, drug utilization, rational drug use and pharmacogenetics. Sweden has a unique opportunity to meet these demands by using national healthcare databases, bio banks, as well as having high levels of expertise in the fields of epidemiologically, pharmacology and other areas. CPE is mainly focusing on drug safety evaluation using data from the Swedish national registers. We have identified five research areas where we in particular can provide expert competence:

- Chronic diseases and biologics
- CNS and drugs
- Drugs during pregnancy and infancy
- Cardiovascular diseases and drugs
- Cancer and drugs.

### Institution details

Experience with collecting data directly from individual patients or respondents:

Yes

Interest in carrying out research that is funded by pharmaceutical companies:

Yes

## Contact

Ulrika Undén ulrika.unden@ki.se



ulrika.unden@ki.se

Johan Reutfors johan.reutfors@ki.se



johan.reutfors@ki.se